October 27, 2017 08:00 AM EDT
Peer Review

Biotech Peer Re­view: Ma­gen­ta on­boards five new VPs; BioIn­vent is hunt­ing for a new CEO

Amber Tong

→ Fol­low­ing a $50 mil­lion se­ries B in April, stem cell trans­plan­ta­tion start­up Ma­gen­ta Ther­a­peu­tics is fill­ing some key roles in its lead­er­ship team …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

Pro­tag­o­nist, Takeda's prof­it shar­ing deal un­der spot­light af­ter Phase 3 blood dis­or­der tri­al win

AD­Cs from a decade-old Sin­ga­pore biotech find new life with $187M

Ab­b­Vie fi­nal­ly en­ters obe­si­ty race with $350M up­front for Gubra’s amylin

No­vo Nordisk signs $354M part­ner­ship with AI-guid­ed biotech for ‘risky’ new meta­bol­ic mech­a­nisms

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times